This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Classification and special reduction | ICD-10: I34 (Nonrheumatic mitral valve disorders) | Special Copayment Reduction: V192 (heart disease special copayment reduction: 5% copayment for up to 30 days from the registration date) |
|---|---|
| Synonyms | Mitral regurgitation (MR), mitral valve prolapse (MVP), mitral stenosis (nonrheumatic), mitral annular calcification (MAC), floppy mitral valve, Barlow syndrome |
| Age of onset | MVP: most common in the 20s–50s; degenerative MR: older adults (60s or older); MAC: 70s or older |
| 1. History | Go to section |
| 2. Causes | Go to section |
| 3. Genetics | Go to section |
| 4. General epidemiology | Go to section |
| 5. Pathophysiology | Go to section |
| 6. Symptoms | Go to section |
| 7. Signs | Go to section |
| 8. Screening | Go to section |
| 9. Diagnosis | Go to section |
| 10. Treatment | Go to section |
| 11. Prognosis | Go to section |
| 12. Prevention | Go to section |
| 13. References | Go to section |
The history of mitral valve disease dates back to the stethoscope era of the 19th century. In 1832 Jean-Baptiste Bouillaud described the association between heart murmurs and valve disease, and for a long time afterward most mitral regurgitation was understood as a sequela of rheumatic fever. Separate recognition of nonrheumatic mitral valve disease became possible only with the advent of echocardiography in the mid-20th century.
The history of mitral valve prolapse (MVP) began in 1966 when John Michael Criley first used the term "prolapse." Around the same time, Barlow and Bosman described a syndrome presenting with a systolic click and late systolic murmur and named it "Barlow syndrome." These two concepts were integrated to establish today's concept of MVP. As echocardiography advanced in the 1980s–90s, the diagnostic criteria for MVP were revised; initially, prevalence was overestimated (5–17% of the general population) based on posterior displacement of the anterior mitral leaflet on M-mode ultrasound. In 1988 Devereux et al. proposed 2D echocardiographic criteria (prolapse ≥2 mm) that took into account the three-dimensional saddle-shaped mitral annulus, and prevalence was reassessed.
Surgical treatment of degenerative mitral regurgitation began with valve replacement in the 1960s, and in the 1980s Carpentier established valve repair techniques, establishing that repair yields superior long-term results compared with replacement. In 2013, with FDA approval of MitraClip percutaneous mitral valve repair technology, a nonsurgical treatment option became available for high-risk patients, and in 2018–2019 the COAPT and MITRA-FR clinical studies prompted discussion of the role of percutaneous treatment in secondary (functional) mitral regurgitation.
The clinical importance of mitral annular calcification (MAC) has been recognized through echocardiographic research since the 1980s, and mitral stenosis and regurgitation due to MAC are now classified as important subtypes of nonrheumatic mitral valve disease.
Nonrheumatic mitral valve disorders (ICD I34) are caused by various causes unrelated to rheumatic fever. ICD I34 is subdivided into I34.0 (mitral regurgitation), I34.1 (mitral valve prolapse), I34.2 (nonrheumatic mitral stenosis), I34.8 (other nonrheumatic mitral valve disorders), and I34.9 (unspecified).
Causes of primary (degenerative) mitral regurgitation: ① Myxomatous degeneration—the structural basis of MVP, causing leaflet thickening and laxity and chordal elongation and rupture. ② Chordal rupture—occurs spontaneously (myxomatous or age-related) or due to trauma and causes acute severe regurgitation. ③ Infective endocarditis—regurgitation due to valve destruction and perforation. ④ Valve damage after radiation exposure. ⑤ Drug-induced (formerly fenfluramine and dexfenfluramine: now withdrawn).
Causes of secondary (functional) mitral regurgitation: The valve itself is structurally normal, but regurgitation occurs due to ventricular dysfunction or left ventricular dilation. ① Ischemic cardiomyopathy (papillary muscle dysfunction or left ventricular dilation after myocardial infarction), ② dilated cardiomyopathy (annular dilation and papillary muscle displacement due to left ventricular remodeling). In secondary MR, the treatment approach differs because the cause is a ventricular lesion rather than the valve itself.
Mitral valve prolapse (MVP): The most common primary mitral valve disease, a condition in which leaflet thickening and chordal laxity due to myxomatous degeneration cause the valve leaflets to prolapse 2 mm or more toward the left atrium during systole. Classic MVP has a leaflet thickness ≥5 mm, and nonclassic MVP < 5 mm.
Mitral annular calcification (MAC): A degenerative calcification process closely associated with cardiovascular risk factors such as advanced age, chronic kidney failure, diabetes, hypertension, and dyslipidemia. MAC can cause mitral stenosis (MAC stenosis) or mitral regurgitation and is also a risk factor for atrial fibrillation, conduction disorders, and endocarditis.
Mitral valve prolapse (MVP) is the best-studied hereditary form of nonrheumatic mitral valve disorder. MVP is divided into sporadic and familial forms, with about 30% of all cases estimated to be familial.
The inheritance pattern of familial MVP is mainly autosomal dominant with incomplete penetrance. Major genetic loci and genes identified to date: ① MMVP1 (16p11.2–p12.1)—autosomal dominant nonsyndromic MVP. ② MMVP2 (11p15.4)—a second nonsyndromic MVP locus. ③ MMVP3 (13q31.3–q32.1). ④ FLNC (filamin C, 7q32.1)—a structural protein of muscle fiber cells; mutations are associated with abnormal valve matrix structure and MVP with arrhythmia. ⑤ DCHS1 (dachsous cadherin-related 1, 11p15)—involved in cell-cell adhesion; DCHS1 mutations are associated with a familial syndrome of MVP with scoliosis. ⑥ FBN1, FBN2 (fibrillin genes)—MVP accompanies Marfan syndrome and the MASS phenotype. ⑦ KCNK3 (TASK-1 potassium channel)—a gene associated with papillary muscle function and MVP-associated arrhythmias.
Genome-wide association studies (GWAS) have reported that single nucleotide variants (SNPs) in TNS1 (tensin 1), LMCD1, MMP2, and others are associated with MVP risk. Recent single-cell RNA sequencing studies are revealing the heterogeneity of valve cell populations and the role of the TGF-β and Notch signaling pathways.
Association of connective tissue disorders with MVP: The prevalence of MVP is significantly higher than in the general population in Marfan syndrome (FBN1), Ehlers-Danlos syndrome (several types; COL3A1 and others), and Loeys-Dietz syndrome (TGFBR1/2). In patients with these connective tissue disorders, structural vulnerability of the valve matrix is the common pathophysiological mechanism of myxomatous degeneration.
As genetic factors in mitral annular calcification (MAC), variants in lipid metabolism-related genes such as LPA (lipoprotein a), the APOE ε4 allele, and PLTP have been reported, overlapping considerably with traditional cardiovascular risk genes.
Nonrheumatic mitral valve disease is the most common cause of valve disease requiring surgery in developed countries. In valve surgery registry data from Europe and North America, degenerative (nonrheumatic) causes account for about 60–70% of all mitral valve surgeries.
Mitral valve prolapse (MVP) is the most common valve disease in the general population, with a prevalence of about 2–3% by 2D echocardiographic criteria (prolapse ≥2 mm). By sex, it is diagnosed slightly more often in women, but men have a higher risk of severe regurgitation and complications. In particular, classic MVP (thick myxomatous degeneration) carries a high risk of chordal rupture, severe regurgitation, and progression to heart failure.
Degenerative mitral regurgitation: The prevalence of moderate or greater mitral regurgitation in the general adult population is about 1.7–2.5% (Framingham Heart Study, 2006). Incidence increases sharply after age 60, and moderate or greater MR is observed in about 10% of those aged 80 or older. Secondary (functional) MR accompanies about 20–30% of patients after myocardial infarction and about 40–60% of patients with dilated cardiomyopathy.
Mitral annular calcification (MAC): In general population echocardiographic studies it is found in about 6–15% of adults, increasing to more than 40% in older adults (70s or older). In patients with chronic kidney failure on hemodialysis, prevalence is high at younger ages and progression is faster.
In Korea, rheumatic mitral valve disease was formerly the main cause of mitral valve surgery, but with economic development, wider antibiotic availability, and the decline of rheumatic fever, the proportion of degenerative causes is increasing. In cardiac surgery data from major Korean hospitals, degenerative causes now account for about 50% or more of surgically treated mitral valve disease. With population aging, MAC-associated mitral valve disorders are also on the rise.
The pathogenesis of nonrheumatic mitral valve disorders differs depending on the type of disease.
Pathogenesis of myxomatous degeneration and MVP: The normal mitral leaflet consists of three layers (fibrosa—collagen, spongiosa—proteoglycans, atrialis—elastin). In myxomatous degeneration, the spongiosa layer thickens, proteoglycans such as dermatan sulfate accumulate, and the structural integrity of collagen fibers is lost. As a result, the valve leaflets thicken (leaflet thickening) and the chordae elongate, eventually leading to formation of a flail leaflet through chordal rupture and severe regurgitation. Overactivation of the TGF-β signaling pathway and abnormal extracellular matrix remodeling due to MMP (matrix metalloproteinase) imbalance are known to be the key molecular mechanisms.
Pathogenesis of ischemic/functional mitral regurgitation: In secondary MR, the valve itself is nearly normal, but left ventricular dilation and deformation (remodeling) due to myocardial infarction or cardiomyopathy cause papillary muscle displacement. When the papillary muscles are pulled toward the apex and posteriorly, chordal tension increases and systolic closure of the leaflets becomes incomplete (tethering mechanism). At the same time, the annulus dilates and the coaptation surface of the leaflets decreases (annular dilatation). The two mechanisms act in combination to produce regurgitation.
Hemodynamic consequences: In chronic severe MR, the left ventricle is subjected to volume overload. Because blood regurgitates into the low-resistance left atrium during systole, the left ventricle initially maintains normal forward stroke volume through compensatory volume-driven dilation and hypertrophy. Over the long term, however, left ventricular systolic function declines, and elevated left atrial pressure leads to pulmonary venous hypertension and pulmonary edema. In acute severe MR (chordal rupture, papillary muscle rupture), there is no time for compensation, and sudden pulmonary edema and cardiogenic shock occur.
Pathogenesis of MAC: MAC is an active calcification process beginning in the fibrofatty tissue of the annulus, involving mechanisms similar to vascular calcification (expression of osteogenesis-related proteins osteopontin and osteocalcin, RANKL/OPG pathway). MAC fixes the base of the leaflets, interfering with normal systolic annular contraction, and restricts leaflet motion, causing stenosis or regurgitation.
Symptoms of nonrheumatic mitral valve disorders differ greatly depending on the degree of regurgitation, course (acute/chronic), left ventricular function, and presence of concomitant atrial fibrillation.
Asymptomatic phase: Most patients with mild to moderate chronic MR and MVP remain asymptomatic for years to decades. Nonspecific chest pain (atypical chest pain) is commonly reported in patients with MVP, but it is often unrelated to coronary artery disease. Some patients with MVP experience palpitations, dizziness, and anxiety, which may be associated with autonomic nervous system dysfunction.
Heart failure symptoms: The most important symptoms in severe MR. Exertional dyspnea is most common and gradually progresses to dyspnea during daily activities and at rest. Orthopnea and paroxysmal nocturnal dyspnea (PND) reflect pulmonary venous hypertension. Fatigue and reduced exercise tolerance are also common. Lower extremity edema appears when right heart failure is present.
Atrial fibrillation-related symptoms: Atrial fibrillation is a common complication in patients with chronic severe MR, causing palpitations, irregular pulse, worsening dyspnea, and fatigue. The onset of atrial fibrillation is an important factor in determining the timing of surgery.
Symptoms of acute severe MR: Chordal rupture, valve destruction due to infective endocarditis, and papillary muscle rupture after acute myocardial infarction cause sudden acute pulmonary edema. Rapid-onset dyspnea, cyanosis, and hypotension appear, constituting a cardiac emergency requiring immediate management.
MAC-related symptoms: MAC itself is mostly asymptomatic, but when MAC-induced mitral stenosis is severe, pulmonary venous hypertension and exertional dyspnea occur. MAC is also associated with conduction disorders (AV block, bundle branch block), which can cause bradycardia and syncope, and it increases the risk of thromboembolism (stroke).
A heart murmur is the most important auscultatory finding of mitral regurgitation. The typical murmur of primary MR is a holosystolic high-pitched murmur, best heard at the apex and radiating to the left axilla and left scapular area. The intensity of the murmur does not directly reflect severity. In acute severe MR, left atrial pressure rises rapidly, so the murmur may weaken in late systole or be heard only in early systole.
In MVP, a characteristic mid-systolic click is heard, followed by a late systolic murmur. In the standing position the click moves earlier (earlier in systole), and with squatting or leg elevation it moves later (later in systole)—this reflects changes in preload and aids in the diagnosis of MVP.
Apical impulse: In chronic severe MR, the apical impulse is displaced inferolaterally to the left due to left ventricular dilation, and a hyperdynamic impulse is palpable. A fourth heart sound (S4) suggests abnormal left ventricular filling, and a third heart sound (S3) reflects volume overload in severe MR.
Lung auscultation: In acute MR or chronic MR with heart failure, crackles are heard at the lung bases.
Blood pressure and pulse: In chronic MR, diastolic pressure may be lowered (wide pulse pressure). In acute severe MR, hypotension and tachycardia are signs of cardiogenic shock. When atrial fibrillation is present, an irregular pulse is observed.
Systemic signs: In MVP associated with Marfan syndrome or Ehlers-Danlos syndrome, connective tissue disease findings such as long limbs, arachnodactyly, joint hypermobility, skin fragility, and lens dislocation are present. In far-advanced heart failure, signs of right heart failure such as peripheral edema, elevated jugular venous pressure, hepatomegaly, and ascites appear.
There is no population-specific screening program for nonrheumatic mitral valve disorders, but it is important to promptly perform appropriate diagnostic tests in patients with a heard murmur or symptoms such as dyspnea and palpitations.
Auscultation: If a systolic murmur or the click-murmur characteristic of MVP is heard on routine physical examination, echocardiography should be performed. Many cases are discovered incidentally in asymptomatic patients.
Electrocardiogram (ECG): Nonspecific, but in MR, P-wave abnormalities (p-mitrale), left ventricular hypertrophy, and ST-T changes may be seen. Atrial fibrillation is a factor that moves up the timing of surgery. In MVP, T-wave inversion or nonspecific ST-T changes may appear in the inferior leads (II, III, aVF), and QT interval prolongation may be associated with the risk of MVP-associated arrhythmic sudden death (MVPS).
Chest X-ray: Left atrial enlargement (widened tracheal carina angle, double density along the right heart border), left ventricular enlargement, and pulmonary venous congestion (perihilar haziness, Kerley B lines) may be observed. MAC appears as eggshell-like calcification at the base of the heart (mitral area).
Transthoracic echocardiography (TTE): The most important primary diagnostic tool. It comprehensively evaluates valve morphology, regurgitation mechanism, prolapsing segments, presence of chordal rupture, regurgitation severity (jet area, proximal isovelocity surface area [PISA], vena contracta), left ventricular and left atrial size and function, and pulmonary artery pressure. The ESC and AHA/ACC guidelines recommend TTE in all patients with a mitral murmur or in patients with dyspnea.
In patients with high-risk connective tissue disorders (Marfan, Ehlers-Danlos, etc.), regular echocardiographic follow-up is recommended regardless of symptoms. Follow-up echocardiography is performed every 2–3 years in patients with MVP and every year or every 6 months in patients with moderate or greater MR.
Echocardiography is central to the diagnosis of nonrheumatic mitral valve disorders. It begins with TTE, adding transesophageal echocardiography (TEE) or three-dimensional echocardiography (3D-echo) as needed.
Criteria for quantitative assessment of mitral regurgitation severity (2017 ASE guideline): ① effective regurgitant orifice area (EROA) ≥0.40 cm² (primary MR) or ≥0.20 cm² (secondary MR), ② regurgitant volume (RVol) ≥60 mL/beat (primary) or ≥30 mL/beat (secondary), ③ regurgitant fraction (RF) ≥50% (primary) or ≥50% (secondary) are defined as severe. A vena contracta width ≥7 mm also suggests severe MR.
Echocardiographic diagnostic criteria for MVP: on the 2D echocardiographic parasternal long-axis view (PLAX view), prolapse of a mitral leaflet ≥2 mm toward the left atrium beyond the plane of the mitral annulus; in classic MVP, leaflet thickness ≥5 mm.
Transesophageal echocardiography (TEE): Essential before valve repair surgery, for clarifying the mechanism of lesions related to flail leaflet, for excluding IE, and for planning percutaneous procedures (MitraClip). 2D and 3D TEE accurately identify the prolapsing segments (Carpentier classification: A1–A3, P1–P3).
Cardiac MRI (CMR): Performed to accurately quantify left ventricular volume and function when echocardiographic image quality is poor or there is discordance in the assessment of regurgitation severity. CMR allows direct measurement of regurgitant volume (phase-contrast velocity mapping).
Exercise stress testing: Can be performed in patients with asymptomatic severe MR to evaluate latent symptoms or changes in pulmonary artery pressure (PASP >60 mmHg during exercise). Exercise stress echocardiography is particularly useful.
Cardiac catheterization: Because the severity of valve disease can be assessed with noninvasive tests, it is now performed mainly to check for concomitant coronary artery disease (preoperative coronary angiography) or to evaluate pulmonary hypertension.
Treatment of nonrheumatic mitral valve disorders is individualized according to symptoms, regurgitation severity, left ventricular function and size, surgical risk, and the feasibility of valve repair.
Medical treatment: No drug corrects mitral regurgitation itself. In MR with heart failure, standard heart failure drug therapy is given, including ACE inhibitors/ARBs (angiotensin receptor blockers), beta-blockers, loop diuretics, and SGLT2 inhibitors. In asymptomatic MR with normal left ventricular function, prophylactic vasodilator therapy is not recommended. In atrial fibrillation, rate or rhythm control and anticoagulation (based on the CHA₂DS₂-VASc score) are given. When MVP-associated arrhythmias (frequent premature ventricular contractions, nonsustained ventricular tachycardia, syncope) are present, beta-blockers or antiarrhythmic drugs are considered. MVP accompanied by repolarization abnormalities on ECG, valve regurgitation, and left ventricular fibrosis (on CMR) carries a high risk of sudden death, so ICD implantation is considered.
Surgical treatment: ① Indications for surgery: symptomatic severe primary MR (LVEF > 30%); asymptomatic severe MR + LVEF ≤60% or LVESD ≥40 mm (ESC 2021/AHA 2021 criteria); asymptomatic severe MR + new-onset atrial fibrillation or resting pulmonary artery systolic pressure >50 mmHg; asymptomatic severe MR with a high likelihood of valve repair and low surgical risk. ② Surgical approach: Valve repair is preferred over replacement, and at experienced centers repair is possible in more than 90% of degenerative MR. Repair techniques include flail leaflet repair (leaflet resection), artificial chordae (neochordae) implantation, and annuloplasty ring implantation. Long-term results of repair are superior to replacement (in terms of survival, risk of reoperation, and preservation of cardiac function).
Percutaneous treatment (MitraClip and TEER): Transcatheter mitral edge-to-edge repair (TEER) is a procedure that uses a metal clip to join the anterior and posterior leaflets, reducing regurgitation. The 2018 COAPT study demonstrated that MitraClip significantly reduced mortality and rehospitalization in heart failure patients with persistent severe secondary MR despite optimal medical therapy (HR 0.62, p<0.001). In contrast, the MITRA-FR study (2018) showed no benefit, highlighting the importance of appropriate patient selection (the proportionate MR concept). Currently, the ESC 2021 and AHA/ACC 2021 guidelines recommend TEER in patients with primary MR at high surgical risk and in appropriately selected patients with secondary MR (Class IIa–IIb).
The prognosis of nonrheumatic mitral valve disorders differs greatly depending on disease type, regurgitation severity, left ventricular function, presence of concomitant atrial fibrillation, and timing of treatment.
Asymptomatic MVP and mild MR: Most remain asymptomatic for long periods with a favorable prognosis. In classic MVP (thick leaflets, moderate to severe MR), the risk of progression to acute severe regurgitation due to chordal rupture is high. MVP-related sudden death (MVPS) is rare, but a true risk group exists, and myocardial fibrosis of the papillary muscles and other areas on CMR has recently been identified as a poor prognostic factor.
Asymptomatic severe primary MR: According to Enriquez-Sarano et al. (NEJM 2005, Mayo Clinic cohort), patients with asymptomatic severe MR followed medically have a high 10-year risk of cardiac death and heart failure, and about 5–10% per year progress to a state requiring surgery. Evidence has accumulated that early surgery (before reaching the LVEF ≤60% or LVESD ≥40 mm criteria) is advantageous for long-term preservation of left ventricular function.
Prognosis after surgery: The long-term results of timely valve repair surgery are excellent, with survival close to normal life expectancy. The 10-year survival is about 75–85%, and the reoperation rate after valve repair is about 5–10% at 10 years. In contrast, prognosis is poor when surgery is performed after LVEF has declined or when atrial fibrillation has become chronic.
Secondary MR: A prognostic indicator reflecting the severity of the underlying heart failure; despite appropriate treatment, 1-year mortality reaches 20–25%. According to COAPT data, the MitraClip procedure can reduce 2-year mortality from about 29% to 21%.
Primary prevention of nonrheumatic mitral valve disorders is limited, but secondary prevention to slow progression and prevent complications is important.
Control of cardiovascular risk factors: Hypertension, dyslipidemia, diabetes, and obesity are actively controlled to slow the progression of MAC and secondary MR. Regular aerobic exercise and smoking cessation also contribute to maintaining cardiovascular health. However, clinical evidence to date that statins or specific drugs slow the progression of MAC or MR is insufficient.
Prevention of infective endocarditis: Patients with severe MR, a history of endocarditis, or a prosthetic valve are at high risk for IE, and antibiotic prophylaxis before appropriate dental procedures (amoxicillin 2 g orally, 30–60 minutes before the procedure) is recommended. Oral hygiene (daily toothbrushing and flossing) is also important.
Appropriate follow-up: Patients with asymptomatic severe MR should undergo regular (every 6 months to 1 year) echocardiographic follow-up to detect declining left ventricular function or onset of atrial fibrillation early and not miss the timing of surgery. Surgery before LVEF ≤60% or LVESD ≥40 mm is reached is advantageous for long-term prognosis.
Management of atrial fibrillation: When atrial fibrillation develops, stroke is prevented with anticoagulation, and cardiac function is maintained with rate and rhythm control. In some patients, early restoration and maintenance of sinus rhythm may help improve prognosis. For atrial fibrillation present at the time of surgery, surgical ablation such as the Maze procedure is performed concomitantly to restore sinus rhythm.
Management of patients with connective tissue disorders: In patients with Marfan syndrome, suppression of aortic dilation with losartan or atenolol, restriction of vigorous contact sports and isometric exercise, and regular echocardiographic and aortic imaging follow-up are important for preventing worsening of MVP and aortic complications.